Novo Nordisk: 9m EPS up 19%

(CercleFinance.com) - Novo Nordisk has announced that sales reached 204bn DKK (about E27bn) in the first nine months of the year, up 23% as reported and +24% at constant exchange rates on the same period a year earlier.


9m EBIT rose 21% to 91bn DKK (+22% at constant exchange rates).

Net profit was up 18% to 72bn DKK, giving EPS of 16.29 DKK, up 19%.

Sales growth is being driven by increasing demand for our GLP-1-based diabetes and obesity treatments, says CEO Lars Fruergaard Jørgensen, who is also very satisfied with the R&D results achieved across the semaglutide portfolio.

Novo Nordisk is targeting sales growth of between 23% and 27% at constant exchange rates for 2024, with EBIT growth of between 21% and 27% at constant exchange rates.

Growth expressed in Danish kronor is now expected to be 1% lower than at CER for sales, and 2% lower for EBIT.


Copyright (c) 2024 CercleFinance.com. All rights reserved.